191 related articles for article (PubMed ID: 32459721)
1. Successful Haploidentical Stem Cell Transplant With Posttransplant Cyclophosphamide in Wiskott-Aldrich Syndrome With Myeloablative Conditioning.
Sharma A; Rastogi N; Kapoor R; Chatterjee G; Yadav SP
J Pediatr Hematol Oncol; 2021 Mar; 43(2):e230-e233. PubMed ID: 32459721
[TBL] [Abstract][Full Text] [Related]
2. Posttransplant cyclophosphamide for haploidentical stem cell transplantation in children with Wiskott-Aldrich syndrome.
Yue Y; Shi X; Song Z; Qin J; Li J; Feng S; Liu R
Pediatr Blood Cancer; 2018 Aug; 65(8):e27092. PubMed ID: 29745014
[TBL] [Abstract][Full Text] [Related]
3. Successful Reduced Intensity Conditioning Alternate Donor Stem Cell Transplant for Wiskott-Aldrich Syndrome.
Thakkar D; Katewa S; Rastogi N; Kohli S; Nivargi S; Yadav SP
J Pediatr Hematol Oncol; 2017 Nov; 39(8):e493-e496. PubMed ID: 28859032
[TBL] [Abstract][Full Text] [Related]
4. Post-transplantation Cyclophosphamide and Sirolimus after Haploidentical Hematopoietic Stem Cell Transplantation Using a Treosulfan-based Myeloablative Conditioning and Peripheral Blood Stem Cells.
Cieri N; Greco R; Crucitti L; Morelli M; Giglio F; Levati G; Assanelli A; Carrabba MG; Bellio L; Milani R; Lorentino F; Stanghellini MT; De Freitas T; Marktel S; Bernardi M; Corti C; Vago L; Bonini C; Ciceri F; Peccatori J
Biol Blood Marrow Transplant; 2015 Aug; 21(8):1506-14. PubMed ID: 26001696
[TBL] [Abstract][Full Text] [Related]
5. Haploidentical Stem Cell Transplantation With Post-transplant Cyclophosphamide for Pediatric Acute Leukemia is Safe and Effective.
Sharma A; Rastogi N; Chatterjee G; Kapoor R; Nivargi S; Yadav SP
J Pediatr Hematol Oncol; 2021 Oct; 43(7):e1033-e1036. PubMed ID: 33306606
[TBL] [Abstract][Full Text] [Related]
6. Successful Haploidentical Stem Cell Transplant With Posttransplant Cyclophosphamide for Hemophagocytic Lymphohistiocytosis.
Kohli S; Rastogi N; Nivargi S; Thakkar D; Katewa S; Yadav SP
J Pediatr Hematol Oncol; 2019 Apr; 41(3):e158-e160. PubMed ID: 30044345
[TBL] [Abstract][Full Text] [Related]
7. Reduced toxicity, myeloablative HLA-haploidentical hematopoietic stem cell transplantation with post-transplantation cyclophosphamide for sickle cell disease.
Wiebking V; Hütker S; Schmid I; Immler S; Feuchtinger T; Albert MH
Ann Hematol; 2017 Aug; 96(8):1373-1377. PubMed ID: 28573314
[TBL] [Abstract][Full Text] [Related]
8. Augmented immunosuppression and PTCY-based haploidentical hematopoietic stem cell transplantation for thalassemia major.
Vellaichamy Swaminathan V; Ravichandran N; Ramanan KM; Meena SK; Varla H; Ramakrishnan B; Jayakumar I; Uppuluri R; Raj R
Pediatr Transplant; 2021 Mar; 25(2):e13893. PubMed ID: 33111490
[TBL] [Abstract][Full Text] [Related]
9. A Conditioning Regimen with Plerixafor Is Safe and Improves the Outcome of TCRαβ
Balashov D; Laberko A; Shcherbina A; Trakhtman P; Abramov D; Gutovskaya E; Kozlovskaya S; Shelikhova L; Novichkova G; Maschan M; Rumiantsev A; Maschan A
Biol Blood Marrow Transplant; 2018 Jul; 24(7):1432-1440. PubMed ID: 29550630
[TBL] [Abstract][Full Text] [Related]
10. HLA-haploidentical stem cell transplantation using posttransplant cyclophosphamide.
Sugita J
Int J Hematol; 2019 Jul; 110(1):30-38. PubMed ID: 31104211
[TBL] [Abstract][Full Text] [Related]
11. Successful Reduced Intensity Allogeneic Transplant With Full Donor Chimerism and Good Quality of Life in Adolescent Patient With Wiskott-Aldrich Syndrome.
Ali S; Gacsadi A; McDougall E; Armstrong C; Krueger J; Schechter T; Ali M
J Pediatr Hematol Oncol; 2017 Jul; 39(5):e267-e269. PubMed ID: 28538502
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic hemopoietic stem cell transplantation (HSCT) for Wiskott-Aldrich syndrome: a report of the Spanish Working Party for Blood and Marrow Transplantation in Children (GETMON).
Muñoz A; Olivé T; Martinez A; Bureo E; Maldonado MS; Diaz de Heredia C; Sastre A; Gonzalez-Vicent M;
Pediatr Hematol Oncol; 2007 Sep; 24(6):393-402. PubMed ID: 17710656
[TBL] [Abstract][Full Text] [Related]
13. Haploidentical bone marrow transplantation in a pediatric patient with Wiskott-Aldrich syndrome. A case report.
Pury S; López Orozco M; Pichichero G; Sasia LV; Morell D; Álvarez MS; Basquiera AL; Mas ME; Salvucci K
Arch Argent Pediatr; 2024 Feb; 122(1):e202310061. PubMed ID: 37471507
[TBL] [Abstract][Full Text] [Related]
14. Comparable outcomes among unmanipulated haploidentical, matched unrelated, and matched sibling donors in BU-based myeloablative hematopoietic stem cell transplantation for intermediate and adverse risk acute myeloid leukemia in complete remission: a single-center study.
Lu Y; Zhao YL; Zhang JP; Xiong M; Cao XY; Liu DY; Sun RJ; Wei ZJ; Zhou JR; Lu DP
Ann Hematol; 2021 Jun; 100(6):1579-1591. PubMed ID: 33236196
[TBL] [Abstract][Full Text] [Related]
15. Bone marrow versus peripheral blood as a graft source for haploidentical donor transplantation in adults using post-transplant cyclophosphamide-A systematic review and meta-analysis.
Yu X; Liu L; Xie Z; Dong C; Zhao L; Zhang J; Gu J; Zhu HH
Crit Rev Oncol Hematol; 2019 Jan; 133():120-128. PubMed ID: 30661648
[TBL] [Abstract][Full Text] [Related]
16. Excellent outcomes following hematopoietic cell transplantation for Wiskott-Aldrich syndrome: a PIDTC report.
Burroughs LM; Petrovic A; Brazauskas R; Liu X; Griffith LM; Ochs HD; Bleesing JJ; Edwards S; Dvorak CC; Chaudhury S; Prockop SE; Quinones R; Goldman FD; Quigg TC; Chandrakasan S; Smith AR; Parikh S; Dávila Saldaña BJ; Thakar MS; Phelan R; Shenoy S; Forbes LR; Martinez C; Chellapandian D; Shereck E; Miller HK; Kapoor N; Barnum JL; Chong H; Shyr DC; Chen K; Abu-Arja R; Shah AJ; Weinacht KG; Moore TB; Joshi A; DeSantes KB; Gillio AP; Cuvelier GDE; Keller MD; Rozmus J; Torgerson T; Pulsipher MA; Haddad E; Sullivan KE; Logan BR; Kohn DB; Puck JM; Notarangelo LD; Pai SY; Rawlings DJ; Cowan MJ
Blood; 2020 Jun; 135(23):2094-2105. PubMed ID: 32268350
[TBL] [Abstract][Full Text] [Related]
17. Hematopoietic stem cell transplantation for Wiskott-Aldrich syndrome: an EBMT Inborn Errors Working Party analysis.
Albert MH; Slatter MA; Gennery AR; Güngör T; Bakunina K; Markovitch B; Hazelaar S; Sirait T; Courteille V; Aiuti A; Aleinikova OV; Balashov D; Bernardo ME; Bodova I; Bruno B; Cavazzana M; Chiesa R; Fischer A; Hauck F; Ifversen M; Kałwak K; Klein C; Kulagin A; Kupesiz A; Kuskonmaz B; Lindemans CA; Locatelli F; Lum SH; Maschan A; Meisel R; Moshous D; Porta F; Sauer MG; Sedlacek P; Schulz A; Suarez F; Vallée TC; Winiarski JH; Zecca M; Neven B; Veys P; Lankester AC
Blood; 2022 Mar; 139(13):2066-2079. PubMed ID: 35100336
[TBL] [Abstract][Full Text] [Related]
18. Favorable Outcome of Post-Transplantation Cyclophosphamide Haploidentical Peripheral Blood Stem Cell Transplantation with Targeted Busulfan-Based Myeloablative Conditioning Using Intensive Pharmacokinetic Monitoring in Pediatric Patients.
Hong KT; Kang HJ; Choi JY; Hong CR; Cheon JE; Park JD; Park KD; Song SH; Yu KS; Jang IJ; Shin HY
Biol Blood Marrow Transplant; 2018 Nov; 24(11):2239-2244. PubMed ID: 29981849
[TBL] [Abstract][Full Text] [Related]
19. Haploidentical Stem Cell Transplant With Post Transplant Cyclophosphamide for Chronic Granulomatous Disease With Thiotepa, Busulfan, and Fludarabine as Conditioning.
Kapoor R; Rastogi N; Yadav SP
J Pediatr Hematol Oncol; 2021 May; 43(4):155-156. PubMed ID: 33235156
[No Abstract] [Full Text] [Related]
20. Haploidentical stem cell transplantation with post-transplant cyclophosphamide for osteopetrosis and other nonmalignant diseases.
Even-Or E; NaserEddin A; Dinur Schejter Y; Shadur B; Zaidman I; Stepensky P
Bone Marrow Transplant; 2021 Feb; 56(2):434-441. PubMed ID: 32855443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
